Please use this identifier to cite or link to this item: https://repository.cihe.edu.hk/jspui/handle/cihe/4040
DC FieldValueLanguage
dc.contributor.authorChan, Stella Sze Waen_US
dc.contributor.otherHu, M.-
dc.contributor.otherKo, S. S. W.-
dc.contributor.otherTam, C. W. Y.-
dc.contributor.otherFok, B. S. P.-
dc.contributor.otherYin, O. Q. P.-
dc.contributor.otherChow, M. S. S.-
dc.contributor.otherTomlinson B.-
dc.date.accessioned2023-06-19T07:29:10Z-
dc.date.available2023-06-19T07:29:10Z-
dc.date.issued2013-
dc.identifier.urihttps://repository.cihe.edu.hk/jspui/handle/cihe/4040-
dc.description.abstractPurpose The pharmacokinetics (PK) of labetalol show wide inter-subject variability, but the genetic causes for this are largely undetermined. This study was performed to examine whether common polymorphisms in UGT1A1, UGT2B7, CYP2C19 and ABCB1 affect the PK of labetalol. Methods The PK of labetalol were determined in 37 Chinese healthy male subjects who took a single oral dose of 200 mg labetalol. Plasma concentrations of labetalol were determined by a high-performance liquid chromatographic method. Subjects were genotyped for the CYP2C19*2 and *3, UGT1A1 *6, *28 and *60, UGT2B7*2 and ABCB1 1236C>T, 2677G>T/A and 3435C>T polymorphisms. Results Subjects with the CYP2C19*2/*2 genotype had a higher peak concentration (255.5 ± 80.1 vs. 156.0 ± 66.3 ng/mL; P < 0.05) and area under the concentration–time curve (AUC<sub>o−∞</sub>; 1,473.7 ± 493.6 vs. 502.8 ± 176.1 ng⋅h/mL; P < 0.001) than subjects with the *1/*1 genotype, and heterozygotes had intermediate values. The common UGT polymorphisms, UGT1A1*6, *60 or *28, and UGT2B7*2 did not result in a significant effect. Subjects with ABCB1 2677TA or TT or ABCB1 3435TT genotypes had higher AUC<sub>o−∞</sub> and lower total clearance than the wild-types (P < 0.05), but this appeared to be related to the distribution of CYP2C19 genotypes. The CYP2C19 genotype appeared to be the only predictor of labetalol concentrations, accounting for approximately 60 % of the total variance in the AUC<sub>o−∞</sub>. Conclusion Our results suggest that the PK of labetalol are significantly affected by the common CYP2C19 polymorphisms in individuals of Chinese ethnicity. Future larger studies are needed to evaluate the effect of CYP2C19 and UGT1A1 polymorphisms on the PK of labetalol stereoisomers and the pharmacodynamic effects.en_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofEuropean Journal of Clinical Pharmacologyen_US
dc.titleCYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjectsen_US
dc.typejournal articleen_US
dc.identifier.doi10.1007/s00228-012-1428-x-
dc.contributor.affiliationSchool of Health Sciencesen_US
dc.relation.issn1432-1041en_US
dc.description.volume69en_US
dc.description.issue4en_US
dc.description.startpage799en_US
dc.description.endpage806en_US
dc.cihe.affiliatedNo-
item.languageiso639-1en-
item.fulltextWith Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_6501-
item.cerifentitytypePublications-
item.openairetypejournal article-
item.grantfulltextopen-
crisitem.author.deptS.K. Yee School of Health Sciences-
Appears in Collections:HS Publication
Files in This Item:
File Description SizeFormat
View Online223 BHTMLView/Open
Check Library Catalogue138 BHTMLView/Open
SFX Query Show simple item record

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.